共查询到20条相似文献,搜索用时 9 毫秒
1.
《Bioorganic & medicinal chemistry letters》2014,24(9):2066-2072
IRAK4 is responsible for initiating signaling from Toll-like receptors (TLRs) and members of the IL-1/18 receptor family. Kinase-inactive knock-ins and targeted deletions of IRAK4 in mice cause reductions in TLR induced pro-inflammatory cytokines and these mice are resistant to various models of arthritis. Herein we report the identification and optimization of a series of potent IRAK4 inhibitors. Representative examples from this series showed excellent selectivity over a panel of kinases, including the kinases known to play a role in TLR-mediated signaling. The compounds exhibited low nM potency in LPS- and R848-induced cytokine assays indicating that they are blocking the TLR signaling pathway. A key compound (26) from this series was profiled in more detail and found to have an excellent pharmaceutical profile as measured by predictive assays such as microsomal stability, TPSA, solubility, and c log P. However, this compound was found to afford poor exposure in mouse upon IP or IV administration. We found that removal of the ionizable solubilizing group (32) led to increased exposure, presumably due to increased permeability. Compounds 26 and 32, when dosed to plasma levels corresponding to ex vivo whole blood potency, were shown to inhibit LPS-induced TNFα in an in vivo murine model. To our knowledge, this is the first published in vivo demonstration that inhibition of the IRAK4 pathway by a small molecule can recapitulate the phenotype of IRAK4 knockout mice. 相似文献
2.
Weijie Hou Yan Ren Zhenhua Zhang Huan Sun Yongfen Ma Bo Yan 《Bioorganic & medicinal chemistry》2018,26(8):1740-1750
A series of novel quinazoline derivatives bearing various C-6 benzamide substituents were synthesized and evaluated as EGFR inhibitors, and most showed significant inhibitory potency against EGFR kinase. In particular, compound 6g possessed potent inhibitory activity against EGFR wild-type (IC50?=?5?nM), and strong antiproliferative activity against HCC827 and Ba/F3 (L858R) cell lines. Kinase profiling against a panel of 365 kinases showed that 6g was highly selective for EGFR. Furthermore, 6g showed desirable properties in assays of liver microsome metabolic stability and cytochromes P450 inhibition and preliminary pharmacokinetic study. The overall attractive profile of 6g made it an interesting compound for further development. 相似文献
3.
Rajeev S. Bhide Alec Keon Carolyn Weigelt John S. Sack Robert J. Schmidt Shuqun Lin Hai-Yun Xiao Steven H. Spergel James Kempson William J. Pitts Julie Carman Michael A. Poss 《Bioorganic & medicinal chemistry letters》2017,27(21):4908-4913
The identification of small molecule inhibitors of IRAK4 for the treatment of autoimmune diseases has been an area of intense research. We discovered novel 4,6-diaminonicotinamides which potently inhibit IRAK4. Optimization efforts were aided by X-ray crystal structures of inhibitors bound to IRAK4. Structure activity relationship (SAR) studies led to the identification of compound 29 which exhibited sub-micromolar potency in a LTA stimulated cellular assay. 相似文献
4.
Shyh-Ming Yang Makoto Yoshioka Jeffrey W. Strovel Daniel J. Urban Xin Hu Matthew D. Hall Ajit Jadhav David J. Maloney 《Bioorganic & medicinal chemistry letters》2019,29(10):1220-1226
Extensive optimization of quinazoline-based lead 8 is described. The structure-activity relationship studies indicate the S-configuration is preferred for the phenylmorpholine substitution. Together with incorporation of a (2-hydroxyl-2-methylpropyl)pyrazole moiety at the 2-position leads to analogs with comparable potency and marked improvement in the pharmacokinetic profile over our previously reported lead compounds. Further in vivo efficacy studies in Kasumi-1 xenograft mouse model demonstrates that the selected inhibitors are well tolerated and highly efficacious in the inhibition of tumor growth. Additionally, the representative analog 19 also demonstrated significant improvement of arthritis severity in a collagen-induced arthritis (CIA) mouse model. These results indicate potential use of these quinazoline-based BET inhibitors for treatment of cancer and inflammatory diseases. A brief discussion of the co-crystallized structure of 19 with BRD4 (BD1) is also highlighted. 相似文献
5.
《Bioorganic & medicinal chemistry letters》2014,24(17):4080-4083
Erythropoietin-producing hepatocellular receptor tyrosine kinase subtype A2 (EphA2) is an attractive therapeutic target for suppressing tumor progression. In our efforts to discover novel small molecules to inhibit EphA2, a class of compound based on 4-substituted quinazoline containing 7-(morpholin-2-ylmethoxy) group was identified as a novel hit by high throughput screening campaign. Structural modification of parent quinazoline scaffolds by introducing substituents on aniline displayed potent inhibitory activities toward EphA2. 相似文献
6.
白细胞介素-1受体相关激酶-2(IRAK2)是调节IL1和Toll样受体信号通路的一个关键性分子,目前对于共价修饰如何调节IRAK2的活性还所知甚少。当与IRAK1共转染时,IRAK2能被共价修饰,在SDS-PAGE分离中呈现出迁移率变慢的多条电泳带。在小鼠骨髓干细胞分化的巨噬细胞(BMMs)中,内源表达的IRAK2在TLR配体刺激下也呈现出类似的共价修饰。而且IRAK2的共价修饰具有磷酸酯酶敏感性,提示大部分为磷酸化修饰。通过体外磷酸激酶活性分析,发现巨噬细胞中表达的IRAK2能在LPS诱导下被激活,成为一个具有激酶活性的调节蛋白。进一步研究发现激酶灭活的IRAK2突变体不能重建IRAK2基因敲除巨噬细胞的功能。通过Western杂交和定量PCR分析,发现IRAK2的激酶活性是介导LPS诱导的信号通路和炎症因子表达所必须的。因此,在LPS诱导下,IRAK2可能被IRAK1进行磷酸化修饰而活化,从而介导下游的信号转导通路、诱导炎症因子的表达。 相似文献
7.
Barlaam B Ducray R Lambert-van der Brempt C Plé P Bardelle C Brooks N Coleman T Cross D Kettle JG Read J 《Bioorganic & medicinal chemistry letters》2011,21(8):2207-2211
Optimization of our bis-anilino-pyrimidine series of EphB4 kinase inhibitors led to the discovery of compound 12 which incorporates a key m-hydroxymethylene group on the C4 aniline. 12 displays a good kinase selectivity profile, good physical properties and pharmacokinetic parameters, suggesting it is a suitable candidate to investigate the therapeutic potential of EphB4 kinase inhibitors. 相似文献
8.
Aisling Dunne Susan Carpenter Constantinos Brikos Pearl Gray Astrid Strelow Holger Wesche Nick Morrice Luke A. J. O'Neill 《The Journal of biological chemistry》2010,285(24):18276-18282
Signal transduction by Toll-like receptor 2 (TLR2) and TLR4 requires the adaptors MyD88 and Mal (MyD88 adaptor-like) and serine/threonine kinases, interleukin-1 receptor-associated kinases IRAK1 and IRAK4. We have found that both IRAK1 and IRAK4 can directly phosphorylate Mal. In addition, co-expression of Mal with either IRAK resulted in depletion of Mal from cell lysates. This is likely to be due to Mal phosphorylation by the IRAKs because kinase-inactive forms of either IRAK had no effect. Furthermore, lipopolysaccharide stimulation resulted in ubiquitination and degradation of Mal, which was inhibited using an IRAK1/4 inhibitor or by knocking down expression of IRAK1 and IRAK4. MyD88 is not a substrate for either IRAK and did not undergo degradation. We therefore conclude that Mal is a substrate for IRAK1 and IRAK4 with phosphorylation promoting ubiquitination and degradation of Mal. This process may serve to negatively regulate signaling by TLR2 and TLR4. 相似文献
9.
Sébastien L. Degorce Rana Anjum Keith S. Dillman Lisa Drew Sam D. Groombridge Christopher T. Halsall Eva M. Lenz Nicola A. Lindsay Michele F. Mayo Jennifer H. Pink Graeme R. Robb James S. Scott Stephen Stokes Yafeng Xue 《Bioorganic & medicinal chemistry》2018,26(4):913-924
We have developed a series of orally efficacious IRAK4 inhibitors, based on a scaffold hopping strategy and using rational structure based design. Efforts to tackle low permeability and high efflux in our previously reported pyrrolopyrimidine series (Scott et al., 2017) led to the identification of pyrrolotriazines which contained one less formal hydrogen bond donor and were intrinsically more lipophilic. Further optimisation of substituents on this pyrrolotriazine core culminated with the discovery of 30 as a promising in vivo probe to assess the potential of IRAK4 inhibition for the treatment of MyD88 mutant DLBCL in combination with a BTK inhibitor. When tested in an ABC-DLBCL model with a dual MyD88/CD79 mutation (OCI-LY10), 30 demonstrated tumour regressions in combination with ibrutinib. 相似文献
10.
Shyh-Ming Yang Daniel J. Urban Makoto Yoshioka Jeffrey W. Strovel Steven Fletcher Amy Q. Wang Xin Xu Pranav Shah Xin Hu Matthew D. Hall Ajit Jadhav David J. Maloney 《Bioorganic & medicinal chemistry letters》2018,28(21):3483-3488
A new series of quinazoline-based analogs as potent bromodomain-containing protein 4 (BRD4) inhibitors is described. The structure-activity relationships on 2- and 4-position of quinazoline ring, and the substitution at 6-position that mimic the acetylated lysine are discussed. A co-crystallized structure of 48 (CN750) with BRD4 (BD1) including key inhibitor-protein interactions is also highlighted. Together with preliminary rodent pharmacokinetic results, a new lead (65, CN427) is identified which is suitable for further lead optimization. 相似文献
11.
Ray P Wright J Adam J Boucharens S Black D Brown AR Epemolu O Fletcher D Huggett M Jones P Laats S Lyons A de Man J Morphy R Sherborne B Sherry L Straten Nv Westwood P York M 《Bioorganic & medicinal chemistry letters》2011,21(4):1084-1088
Rho kinase is an important target implicated in a variety of cardiovascular diseases. Herein, we report the optimisation of the fragment derived ATP-competitive ROCK inhibitors 1 and 2 into lead compound 14A. The initial goal of improving ROCK-I potency relative to 1, whilst maintaining a good PK profile, was achieved through removal of the aminoisoquinoline basic centre. Lead 14A was equipotent against both ROCK-I and ROCK-II, showed good in vivo efficacy in the spontaneous hypertensive rat model, and was further optimised to demonstrate the scope for improving selectivity over PKA versus hydroxy Fasudil 3. 相似文献
12.
Debasis Das Lingzhi Xie Jingbing Wang Xin Xu Zonghua Zhang Jingli Shi Xiaoyong Le Jian Hong 《Bioorganic & medicinal chemistry letters》2019,29(4):591-596
Overexpression of EGFR and HER2 are observed in many breast, ovarian, colon and prostate cancers. The second and third generation irreversible EGFR/HER2 dual kinase inhibitors became popular after the approval of Afatinib by FDA to overcome the mutation related problem. To find efficacious drug candidates, a series of novel quinazoline derivatives were designed, synthesized and evaluated as dual EGFR/HER2 tyrosine kinase (TK) inhibitors. Selected twenty four compounds were reported here with significant inhibitory activities against EGFR/HER2 tyrosine kinases. Several compounds showed nanomolar IC50 values. In vitro studies of quinazoline derivatives were done on NCI-H1975, HCC827, A431, MDA MB-453 cell lines. The compounds 1a, 1d and 1v were found more potent compared to standard drug afatinib. In vivo efficacy study of 1d on nude mice NCI-H1975 tumour xenograft model was discussed. 相似文献
13.
Yazhou Wang Wei Huang Minhang Xin Pan Chen Li Gui Xinge Zhao Feng Tang Jia Wang Fei Liu 《Bioorganic & medicinal chemistry》2017,25(1):75-83
Janus kinases inhibitor is considered to have therapeutic potential for the treatment of oncology and immune-inflammatory diseases. Two series of 4-(2-benzofuranyl)pyrimidin-2-amine and 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl)pyrimidin-2-amine derivatives have been designed and synthesized. Primary SAR studies resulted in the discovery of a novel class of 4,5,6,7-tetrahydrofuro[3,2-c]pyridine based JAK2 inhibitors with higher potency (IC50 of 0.7 nM) and selectivity (>30 fold) to JAK3 kinase than tofacitinib. 相似文献
14.
《Bioorganic & medicinal chemistry letters》2019,29(17):2516-2524
Detailed structure activity relationship of two series of quinazoline EHMT1/EHMT2 inhibitors (UNC0224 and UNC0638) have been elaborated. New and active alternatives are presented for the ubiquitous substitution patterns found in literature for the linker to the lysine mimicking region and the lysine mimic itself. These findings could allow for advancing EHMT1/EHMT2 inhibitors of that type beyond tool compounds by fine-tuning physicochemical properties making these inhibitors more drug-like.. 相似文献
15.
Joel T. Arcari Jean S. Beebe Martin A. Berliner Vincent Bernardo Merin Boehm Gary V. Borzillo Tracey Clark Bruce D. Cohen Richard D. Connell Heather N. Frost Deborah A. Gordon William M. Hungerford Shefali M. Kakar Aaron Kanter Nandell F. Keene Elizabeth A. Knauth Susan D. LaGreca Yong Lu Jinshan M. Chen 《Bioorganic & medicinal chemistry letters》2013,23(10):3059-3063
The synthesis and biological evaluation of novel Tie-2 kinase inhibitors are presented. Based on the pyrrolopyrimidine chemotype, several new series are described, including the benzimidazole series by linking a benzimidazole to the C5-position of the 4-amino-pyrrolopyrimidine core and the ketophenyl series synthesized by incorporating a ketophenyl group to the C5-position. Medicinal chemistry efforts led to potent Tie-2 inhibitors. Compound 15, a ketophenyl pyrrolopyrimidine urea analog with improved physicochemical properties, demonstrated favorable in vitro attributes as well as dose responsive and robust oral tumor growth inhibition in animal models. 相似文献
16.
Jiho Song Soyeon Jang Jung Wuk Lee Danbee Jung Seul Lee Kyung Hoon Min 《Bioorganic & medicinal chemistry letters》2019,29(3):477-480
Discovery of mutant-selective kinase inhibitors is one of the challenges in medicinal chemistry and is a main issue for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. We tried to improve the selectivity of pan-HER inhibitors for mutant EGFRs. Utilizing click chemistry, triazole-tethered quinazoline derivatives were synthesized, based on a quinazoline scaffold showing pan-HER inhibition. The representative compound 5j exhibited 17- and 52-fold improved selectivity for EGFR L858R/T790M over wild-type EGFR and HER2, respectively, and demonstrated 6.7-fold more potent antiproliferative activity against PC9 cells harboring EGFR-activating mutation than gefitinib. Although the described quinazolines did not surpass pyrimidines as 3rd generation EGFR inhibitors in terms of selectivity for mutant EGFRs, our approach might provide information that would help in the identification of mutant-selective compounds among pan-HER inhibitors using the quinazoline scaffold. 相似文献
17.
Sleebs BE Nikolakopoulos G Street IP Falk H Baell JB 《Bioorganic & medicinal chemistry letters》2011,21(19):5992-5994
4-Aminobenzothieno[3,2-d]pyrimidines were previously identified in a high throughput screening campaign as LIMK1 inhibitors. Scaffold reversal led to the identification of a series of simple 5,6-substituted 4-aminothieno[2,3-d]pyrimidines with low micromolar inhibition of LIMK1. 相似文献
18.
Yang Li Jie Xiao Qizhi Zhang Wenmei Yu Mengqin Liu Yu Guo Jun He Yunmei Liu 《Bioorganic & medicinal chemistry》2019,27(3):568-577
Quinazoline was originally utilized as an anti-tumor treatment, and its various derivatives can be directly extracted from plants. In recent years, protein kinases (PK) have been well recognized in the development of tumor drugs. Functionally, PK serves a vital role in the apoptosis, proliferation, differentiation, migration and cell cycle of tumor cells. Due to its good physicochemical properties, quinazoline skeleton, a superior type of PK inhibitor, has been extensively used in anti-tumor drug design. An increasing number of studies on quinazoline synthesis have been reported and used by different groups to effectively develop novel derivatives. Thus, several studies have been approved for the use of quinazoline derivatives as inhibitors of other kinases, including Src and histone deacetylase. The aim of the present review was to summarize the mechanism of quinazoline compounds as PK inhibitors, their biological structure-activity relationship such as the substituted quinazoline compounds with different functional groups in the apoptotic process, and their effect on the proliferation of tumor cells. The development of novel agents based on the antitumor functions of quinazoline molecular compounds may improve the clinical outcomes of the affected population, particularly in patients with cancer. 相似文献
19.
p21-activated kinase 4 (PAK4) is a serine–threonine protein kinase which plays an important role in a wide variety of human diseases including cancer. The inhibition of this kinase is of great interest for the treatment of cancer. In the present study, we report three pharmacophore models of PAK4 based on a small set of PAK4 inhibitors, a crystal structure of PAK4 and a docked complex between PAK4 and a potent inhibitor. These results might provide useful and reliable tools in identifying structurally diverse compounds with desired biological activity. 相似文献
20.
《Bioorganic & medicinal chemistry》2014,22(17):4735-4744
Both c-Met and VEGFR-2 are important targets for the treatment of cancers. In this study, a series of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinazolin-4-amine derivatives were designed and identified as dual c-Met and VEGFR-2 inhibitors. Among these compounds bearing quinazoline and benzimidazole fragments, compound 7j exhibited the most potent inhibitory activity against c-Met and VEGFR-2 with IC50 of 0.05 μM and 0.02 μM, respectively. It also showed the highest anticancer activity against the tested cancer cell lines with IC50 of 1.5 μM against MCF-7 and 8.7 μM against Hep-G2. Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the ATP-binding site of c-Met and VEGFR-2, which demonstrates that compound 7j is a potential agent for cancer therapy deserving further researching. 相似文献